Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Viking Therapeutics, Inc. (VKTX) had Income from Continuous Operations of $-85.89M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-85.89M |
|
-- |
|
-- |
|
$100.83M |
|
$-100.83M |
|
$14.93M |
|
$-85.89M |
|
$-85.89M |
|
$-85.89M |
|
|
Income from Continuous Operations |
$-85.89M |
$-85.89M |
|
$-85.89M |
|
$-100.83M |
|
$-108.65M |
|
94.35M |
|
94.35M |
|
$-0.91 |
|
$-0.91 |
|
| Balance Sheet Financials | |
$367.23M |
|
-- |
|
$1.26M |
|
$368.49M |
|
$19.14M |
|
-- |
|
$0.94M |
|
$20.07M |
|
$348.42M |
|
$348.42M |
|
$348.42M |
|
100.11M |
|
| Cash Flow Statement Financials | |
$-73.38M |
|
$-179.09M |
|
$271.38M |
|
$36.63M |
|
$55.52M |
|
$18.88M |
|
$16.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-73.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.65% |
|
-24.65% |
|
-23.31% |
|
-24.65% |
|
$3.48 |
|
$-0.78 |
|
$-0.78 |
|